Imago BioSciences, Inc. Employee Directory
Biotechnology ResearchCalifornia, United States11-50 Employees
Imago BioSciences, Inc. is a biotechnology research company located in South San Francisco, California, focused on developing drugs to manage proliferative diseases of the bone marrow caused by acquired mutations in blood stem cells. The company's core program involves inhibitors of lysine-specific demethylase 1 (LSD1), with bomedemstat (IMG-7289) as its lead compound studied for acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms including myelofibrosis. Its therapeutic scope includes acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, myelofibrosis, and essential thrombocythemia, reflecting a focus on abnormal bone marrow cell growth and function. In 2022, Merck acquired Imago Biosciences in a transaction valued at $1.35 billion. The company lists a workforce of 11 to 50 employees and maintains a website at imagobio.com.